2019 annual financial data
CRISPR Therapeutics 2019 Operating margin
CRISPR Therapeutics 2019 operating margin with verified reported values.
Direct answer
Operating margin was 16.14%.
Operating income was 46,740,000 USD and net income was 66,858,000 USD.
Operating cash flow was 56,677,000 USD.
Get free CRISPR Therapeutics email updates.
Bullstory sends one daily email when new analysis or important company news is available.
Verified data
- Revenue
- 289,590,000 USD
- Operating income
- 46,740,000 USD
- Net income
- 66,858,000 USD
- Operating cash flow
- 56,677,000 USD